reports
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trial...
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week mainten...
Abivax Announces Annual General Meeting Details as Company Advances To...
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage ...
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directo...
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...
- Ahmed Ben Salem
- Baptiste Lebacq
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALFOC FOCUS HOME INTERACTIVE SA
NK IMERYS SA
AAL ANGLO AMERICAN PLC
APAML APERAM SA
ATO ATOS SE
OUT1V OUTOKUMPU OYJ
BFIT BASIC-FIT NV
SSAB A SSAB AB CLASS A
EVT EVOTEC SE
FGA FIGEAC AERO SA
SZG SALZGITTER AG
WHA WERELDHAVE N.V.
GOE GROUPE GORGE SA
GLO GL EVENTS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
ICAD ICADE SA
SUN SULZER AG
NDA AURUBIS AG
SLIGR SLIGRO FOOD GROUP N.V.
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SAX STROEER SE & CO. KGAA
CON CONZZETA AG
11B 11 BIT STUDIOS S.A.
SIFG SIF HOLDING NV
RIO RIO TINTO PLC
MAU ETABLISSEMENTS MAUREL & PROM SA
FTG111 FLATEXDEGIRO AG
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
NSI NSI N.V.
THEP THERMADOR HOLDING SA
DSC1 DUTCH STAR C SHAR
FAST FASTNED
WINE PURCARI WINERIES PCL
OVH OVH GROUPE
ALVGO VOGO SA
MFEA MEDIASET NV
PLX PLUXEE NV
ORP ORPEA
- Ahmed Ben Salem
- Baptiste Lebacq
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALFOC FOCUS HOME INTERACTIVE SA
NK IMERYS SA
AAL ANGLO AMERICAN PLC
APAML APERAM SA
ATO ATOS SE
OUT1V OUTOKUMPU OYJ
BFIT BASIC-FIT NV
SSAB A SSAB AB CLASS A
FGA FIGEAC AERO SA
SZG SALZGITTER AG
WHA WERELDHAVE N.V.
GOE GROUPE GORGE SA
GLO GL EVENTS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
ICAD ICADE SA
SUN SULZER AG
NDA AURUBIS AG
SLIGR SLIGRO FOOD GROUP N.V.
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SAX STROEER SE & CO. KGAA
CON CONZZETA AG
11B 11 BIT STUDIOS S.A.
SIFG SIF HOLDING NV
RIO RIO TINTO PLC
MAU ETABLISSEMENTS MAUREL & PROM SA
FTG111 FLATEXDEGIRO AG
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
NSI NSI N.V.
THEP THERMADOR HOLDING SA
DSC1 DUTCH STAR C SHAR
FAST FASTNED
WINE PURCARI WINERIES PCL
OVH OVH GROUPE
ALVGO VOGO SA
MFEA MEDIASET NV
PLX PLUXEE NV
ORP ORPEA
- Jeremy Garnier
- Jeremy Garnier
EQS-News: Abivax publishes financial reports with the French and U.S....
EQS-News: ABIVAX / Key word(s): Annual Report Abivax publishes financial reports with the French and U.S. securities regulatory agencies 26.03.2025 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms t...
Abivax publishes financial reports with the French and U.S. securities...
Abivax publishes financial reports with the French and U.S. securities regulatory agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement...
Esker est nommée “Challenger” dans le Magic Quadrant™ 2025 de Gartner®...
Esker est nommée “Challenger” dans le Magic Quadrant™ 2025 de Gartner® pour les suites Source-to-Pay Lyon, France, le 26 mars 2025 – , la plateforme de référence pour la digitalisation des directions Finance et Achats et Service Client, annonce sa nomination en tant que “Challenger” dans le Magic Quadrant™ 2025 de Gartner® pour la suite Source-to-Pay. Le rapport de Gartner a évalué 12 fournisseurs selon un large éventail de critères, plaçant Esker en qualité de “Challenger” pour sa capacité d'exécution et l'exhaustivité de sa vision. Cette distinction récompense la progression rapide d’Es...
- Stephane Beyazian
- Stephane Beyazian
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
Abivax: 1 director
A director at Abivax bought 35,456 shares at 0.000EUR and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Esker est nommée “Leader” dans le tout premier Magic Quadrant™ de Gart...
Esker est nommée “Leader” dans le tout premier Magic Quadrant™ de Gartner® pour les applications Accounts Payable Lyon, France, 24 mars 2025 – , la plateforme de référence pour la digitalisation des directions Finance et Achats et Service Client, annonce sa nomination en tant que "Leader" dans le Magic Quadrant™ 2025 de Gartner® pour les applications Accounts Payable (dématérialisation du traitement des factures fournisseurs). Le rapport de Gartner® a évalué 14 fournisseurs en fonction de leur capacité d'exécution et de leur vision stratégique. Esker se distingue en tant que "Leader", un...
EQS-News: Abivax Announces Full Year 2024 Financial Results
EQS-News: ABIVAX / Key word(s): Annual Results Abivax Announces Full Year 2024 Financial Results 24.03.2025 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Announces Full Year 2024 Financial Results Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France – March 24, 2025 – 8:...
Abivax Announces Full Year 2024 Financial Results
Abivax Announces Full Year 2024 Financial Results Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France – March 24, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on d...
- Emna Ben Bdira
- Maxime Kogge
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
AUTN AUTONEUM HOLDING AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
BFIT BASIC-FIT NV
OSE OSE IMMUNOTHERAPEUTICS SA
SSAB A SSAB AB CLASS A
GYC GRAND CITY PROPERTIES SA
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
TUB TUBACEX S.A.
ERG ERG S.P.A.
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
DIC DIC ASSET AG
RIO RIO TINTO PLC
DUFN DUFRY AG
BHP BHP GROUP LTD
MDM MAISONS DU MONDE SA
AMAG AMAG AUSTRIA METALL AG
THEP THERMADOR HOLDING SA
ORP ORPEA
SPG SPRINGER NATURE AG & CO. KGAA
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.